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Neurobiology of Disease

Early Stage Drug Treatment That Normalizes
Proinflammatory Cytokine Production Attenuates Synaptic
Dysfunction in a Mouse Model That Exhibits Age-Dependent
Progression of Alzheimer’s Disease-Related Pathology
Adam D. Bachstetter,1 Christopher M. Norris,1,2 Pradoldej Sompol,1 Donna M. Wilcock,1,3 Danielle Goulding,1
Janna H. Neltner,1,4 Daret St. Clair,1,5,7 D. Martin Watterson,8 and Linda J. Van Eldik1,6
1

Sanders-Brown Center on Aging, Departments of 2Molecular and Biomedical Pharmacology, 3Physiology, 4Pathology, 5Toxicology, and 6Anatomy and
Neurobiology, and 7Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40536, and 8Department of Molecular Pharmacology and
Biological Chemistry, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611

Overproduction of proinflammatory cytokines in the CNS has been implicated as a key contributor to pathophysiology progression in
Alzheimer’s disease (AD), and extensive studies with animal models have shown that selective suppression of excessive glial proinflammatory cytokines can improve neurologic outcomes. The prior art, therefore, raises the logical postulation that intervention with drugs
targeting dysregulated glial proinflammatory cytokine production might be effective disease-modifying therapeutics if used in the
appropriate biological time window. To test the hypothesis that early stage intervention with such drugs might be therapeutically
beneficial, we examined the impact of intervention with MW01-2-151SRM (MW-151), an experimental therapeutic that selectively
attenuates proinflammatory cytokine production at low doses. MW-151 was tested in an APP/PS1 knock-in mouse model that exhibits
increases in AD-relevant pathology progression with age, including increases in proinflammatory cytokine levels. Drug was administered
during two distinct but overlapping therapeutic time windows of early stage pathology development. MW-151 treatment attenuated the
increase in microglial and astrocyte activation and proinflammatory cytokine production in the cortex and yielded improvement in
neurologic outcomes, such as protection against synaptic protein loss and synaptic plasticity impairment. The results also demonstrate
that the therapeutic time window is an important consideration in efficacy studies of drugs that modulate glia biological responses
involved in pathology progression and suggest that such paradigms should be considered in the development of new therapeutic regimens that seek to delay the onset or slow the progression of AD.

Introduction
Alzheimer’s disease (AD) and related neurodegenerative disorders
have an unmet need for therapies that alter disease progression. Evidence suggests that disease progression involves uncontrolled glial
activation and neuroinflammation that contribute to neuronal/synaptic dysfunction, which in turn drives a vicious cycle of further glial
activation and neuronal damage (Mrak and Griffin, 2005). Dissecting this cycle to find points of potential therapeutic intervention is
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compounded by the complexity of this multifactorial disease, the
multiple roles of glia in homeostasis and host defense, and the diversity of inflammatory and immune response mechanisms (Nelson et
al., 2009, 2011; Cameron and Landreth, 2010; Huang and Mucke,
2012; Wyss-Coray and Rogers, 2012).
The diverse array of physiological functions that glia perform,
which are context dependent, complicates the interpretation of
experimental investigations and clinical observations related to
AD pathology. For example, astrocytes and microglia interact
with neurons at the synapse to modulate synaptic function and
plasticity (Eroglu and Barres, 2010; Tremblay et al., 2011) and are
also vital for host defense mechanisms and response to stress
(Ransohoff and Perry, 2009). Therefore, health and homeostasis,
disease progression and susceptibility, and therapeutic interventions involve a delicate balance in which glial responses must be
modulated within a dynamic range.
Related to disease progression, extended overproduction of
proinflammatory cytokines such as IL-1␤ can be particularly detrimental to neuronal function (Shaftel et al., 2008; Hein et al.,
2010; Kitazawa et al., 2011). The potential for amelioration of
cytokine-induced neuronal dysfunction through therapeutic in-
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tervention was shown by Hu et al. (2007) with the development
of a small molecule experimental therapeutic, MW01-2-151SRM
(here termed MW-151). MW-151 is a selective suppressor of ␤
amyloid (A␤)-induced glia proinflammatory cytokine production, with resultant attenuation of the cytokine-induced loss of
synaptic marker proteins (e.g., synaptophysin and PSD-95) and
cognitive deficits (Hu et al., 2007). A major unmet challenge in
the field, however, is the question of a therapeutic time window in
progressive neurological disorders like AD. The therapeutic time
window is a component of drug dosing, a fundamental aspect of
the pharmacological basis of drug action, and is linked to the
clinical principle of pathology progression. For example, an optimal time window for therapeutic intervention is generally during a peak activity change in the targeted pathway involved in
pathology progression.
To address the issue of whether glial activation and proinflammatory cytokine increases might be an early stage pathology
progression feature that could be modulated by drugs such as
MW-151 with resultant improvement in neurologic endpoints,
we examined an APP/PS1 humanized knock-in mouse model
that exhibits age-dependent AD pathology progression. We
found that proinflammatory cytokines begin to increase early in
the pathology progression and that repeat dose intervention with
MW-151 starting during this period resulted in significantly improved outcomes. While improvements were also seen with later
short-term intervention, the earlier and more prolonged intervention yielded more robust effects. Neither dosing paradigm
had a detectable effect on amyloid plaque load or A␤ levels. The
results indicate that selective inhibition of increasing proinflammatory cytokine production early in disease progression is beneficial at maintaining synaptic function.

Materials and Methods
Synthesis of MW-151. MW01-2-151SRM [2-(4-(4-methyl-6-phenylpyridazin3-yl)piperazin-1-yl)pyrimidine] was synthesized and characterized as reported
previously (Hu et al., 2007). The active pharmaceutical used for biological
studies was the dihydrochloride hydrate form of the water-soluble, acidic
drug. Low doses per administration were employed as noted and are
similar to those used previously for efficacy in diverse animal models of
CNS diseases that involve excessive proinflammatory cytokine production as part of the pathology progression mechanism, including a model
of early AD (Hu et al., 2007), TBI (Lloyd et al., 2008; Chrzaszcz et al.,
2010), multiple sclerosis (Karpus et al., 2008), and seizures (SomeraMolina et al., 2007, 2009) at low doses similar to those used in this study.
APP/PS1 knock-in mice. The AD mouse model used is the APP NLh/NLh ⫻
PS1 P264L/P264L mutant mice originally developed at Cephalon (Flood et
al., 2002). This double mutant mouse was generated by using gene targeting knock-in (KI) technology to introduce the Swedish FAD K670N/
M671L mutations and humanize the mouse A␤ sequence (NLh) and to
introduce the proline to leucine (P264L) mutation in the mouse PS-1
gene (Reaume et al., 1996; Siman et al., 2000). Expression of both genes is
driven by the endogenous promoters, and thus this model shows AD
pathology without APP or PS1 overproduction. The APP/PS1 KI mice
were maintained on a CD-1/129 background, and wild-type (WT) mice
were obtained from heterozygous APP/PS1 matings and maintained as a
separate line for ⬎20 generations of inbred mice used as controls. Mice
were monitored for maintenance of the appropriate genotypes by PCR
analysis of tail snip DNA (Anantharaman et al., 2006). Mice were maintained under 12 h light/dark cycles and provided food and water ad
libitum. All animal protocols followed the principles of animal care and
experimentation in the Guide for the Care and Use of Laboratory Animals,
and were approved by the Institutional Animal Care and Use Committee
of the University of Kentucky (Lexington, KY).
Treatment of mice. MW-151 was dissolved in 0.9% sterile NaCl (saline;
Hospira NDC 0409-4888-10). Two experimental paradigms were used to
test MW-151 efficacy in the APP/PS1 mice. In the extended administra-
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tion prevention study (chronic intervention paradigm), MW-151 was
administered at a low dose (2.5 mg/kg) by intraperitoneal (i.p.) injection
three times per week (Monday, Wednesday, Friday), beginning when
mice were 6 months old and ending at 11 months. In the short-term
treatment study (acute intervention paradigm), MW-151 (2.5 mg/kg)
was administered i.p. to 11-month-old mice once daily for 1 week. Controls included APP/PS1 KI or WT mice administered vehicle control
(saline). To conserve on animal numbers, WT mice were not administered MW-151. Each experimental group (WT plus vehicle, APP/PS1 KI
plus vehicle, APP/PS1 KI plus MW-151) started with 12 mice of either
sex, and the numbers of males and females in each group were matched as
closely as possible.
Euthanasia and brain tissue harvesting. Mice were euthanized with an
overdose of sodium pentobarbital and transcardially perfused with icecold PBS for 5 min. The brains were rapidly removed and bisected along
the sagittal plane. The right hemisphere was further dissected and flash
frozen in liquid nitrogen and stored at ⫺80°C for subsequent biochemical evaluation. The left hemisphere was immersion fixed in 4% paraformaldehyde overnight before cryoprotection in a 30% sucrose/PBS
solution.
Biochemical endpoint analyses. Neocortical tissue was homogenized
using an Omni TH homogenizer in a lysis buffer (1:10 w/v) containing
PBS, 1 mM EDTA, and protease inhibitors (1 mM PMSF, 1 g/ml leupeptin). Extracts were centrifuged at 12,000 ⫻ g for 20 min at 4°C in a
Beckman Microfuge 18, and supernatants were used as the PBS soluble
fraction. Pellets were suspended and rehomogenized in a detergentcontaining lysis buffer (tissue protein extraction reagent with Halt Protease and Phosphatase Inhibitor Cocktail; Thermo Scientific) at the same
volume used for the first homogenization. Extracts were centrifuged at
12,000 ⫻ g for 20 min at 4°C, and supernatants were used for measurement of synaptic proteins in the detergent-soluble fraction. The pellet
was then resuspended and rehomogenized in 70% formic acid (FA). The
FA homogenate was centrifuged at 1,000,000 ⫻ g at 4°C for 60 min. The
supernatant was neutralized 1:20 with 1 M Tris (pH11) and used as the FA
soluble fraction. Levels of A␤40 and A␤42 were measured by ELISA assay
using kits from Meso Scale Discovery (MSD) according to the manufacturer’s instructions. Levels of cytokines (IL-1␤ and IL-10) were measured
by ELISA assay using kits from MSD according to the manufacturer’s
instructions with minor modifications. Briefly, 50 l of the PBS soluble
fraction was loaded per well of the MSD plate (100 –200 g of protein).
The sample was incubated in the plate overnight at 4°C. All incubation
steps were done using an Eppendorf MixMate at 1000 rpm. Cytokine
levels were normalized to the total amount of protein in the sample
loaded as determined by BCA Protein Assay (Thermo Scientific). The
detection limits of the MSD assays are 1.5 pg/ml for IL-1␤ and 42 pg/ml
for IL-10 in serum/plasma.
Levels of synaptic proteins were measured by Western blots as described previously (Xing et al., 2011). Briefly, 1 g of the detergentsolubilized fraction was prepared in SDS buffer (LI-COR Biosciences ).
The sample was separated on a 10% NuPAGE Novex Bis-Tris Midi Gel
(Invitrogen). Proteins were transferred to nitrocellulose membrane using a dry blotting system (iBlot, Invitrogen). Blots were probed using
reagents and manufacturer recommendations for Odyssey Infrared Imaging System (LI-COR Biosciences). Blots were probed for the following
primary antibodies: rabbit anti-PSD95 (1:2000, Cell Signaling Technology, catalog no. 3450); mouse anti-synaptophysin (clone SY38) (1:
30,000, Millipore, catalog no. MAB5258); rabbit anti-syntaxin 1 (1:
100,000, Millipore, catalog no. ab5820); mouse anti-SNAP 25 (clone 20)
(1:10,000, BD Biosciences, catalog no. 610366). Rabbit anti-GAPDH
(clone 14C10) (1:10,000, Cell Signaling Technology, catalog no. 2118)
was used as a loading control. Blots were visualized and analyzed on the
Odyssey Infrared Imaging System (LI-COR Biosciences), and integrated
intensity values were used in statistics.
For gene expression, dissected neocortical tissues stored at ⫺80°C
were used for RNA isolation using RNeasy mini-columns (Qiagen, catalog no. 74104) with on-column DNase treatment (Qiagen, catalog no.
79254) according to the manufacturer’s protocol. RNA quantity and
quality were determined using A260/A280 readings by NanoDrop (Thermo Scientific). Reverse transcription (RT) was done following the manufacturer’s pro-
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tocol using High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, catalog no. 4368814). A no template and a no RT control were
conducted to control for contamination. Real-time PCR was performed using
the TaqMan Gene Expression Assay Kit (Applied Biosystems, catalog no.
4444964) according to the manufacturer’s instructions on a ViiA 7 Real-Time
PCRSystem(AppliedBiosystems).ThefollowingTaqManprobes(AppliedBiosystems) were used: GFAP (Mm00546086_m1), S100B (Mm00485897_m1),
vimentin (Mm01333430_m1), Actb (Mm00607939_s1), and IL-1␤
(Mm00434228_m1)(seeTable1).Relativegeneexpressionwascalculatedbythe
2 ⫺⌬⌬CT method.
Immunohistochemical staining. Coronal sections (30 m) of the left
hemisphere were made using a sliding microtome and a freezing stage
and stored in cryoprotectant at ⫺20°C. Staining procedures were conducted on free-floating sections using every twelfth section of the entire
left cerebral cortex. Primary and secondary antibodies were diluted in 3%
normal goat serum (NGS) (LAMPIRE Biological Laboratories, catalog
no. 7332500) with 0.2% Triton X-100. Amyloid plaque burden was detected by rabbit polyclonal anti-A␤ N-terminal antibody (1:10,000, Invitrogen, catalog no. 44338100). Sections were pretreated with 70%
formic acid and endogenous peroxidase activity was quenched with 3%
H2O2 in methanol, before the tissue blocking in 10% NGS with 0.2%
Triton X-100. The biotinylated secondary antibody (1:500, Jackson ImmunoResearch Laboratories, catalog no. 111-065-144) was amplified using avidin-biotin substrate (ABC solution, Vector Laboratories catalog
no. PK-6100) followed by color development in 3,3⬘-diaminobenzidine
tetra-hydrochloride (DAB; Sigma, catalog no. D5637). Glial activation
was detected with the following antibodies: rabbit anti-GFAP (1:10,000
Dako, catalog no. Z0334) for astrocytes and rabbit anti-IBA1 (1:10,000,
Wako, catalog no. 019-19741) for microglia. Endogenous peroxidase
activity was quenched with 3% H2O2 in methanol, followed by blocking
in 10% NGS with 0.2% Triton X-100. The horseradish peroxidase secondary antibodies (1:500, Jackson ImmunoResearch Laboratories, catalog no. 111-035-003) were visualized with DAB.
Quantitative image analysis of immunohistochemical stains. The Aperio
ScanScope XT digital slide scanner was used to image the entire stained
slide at 20⫻ magnification to create a single high-resolution digital image. The neocortex and hippocampus were outlined using the Aperio
ImageScope software. The Aperio-positive pixel count algorithm (version 9) was used to quantify the amount of specific staining in the region.
The number of positive pixels was normalized to the number of total
pixels (positive and negative) to account for variations in the size of the
region sampled. The Aperio nuclear algorithm (version 9) was used to
quantify the number of cells or the number and size of A␤ plaques in the
outlined region. To quantify the number of plaques as a function of size,
a threshold was set in the nuclear algorithm so only plaques that were
contained in the size bin would be quantified. Color and intensity thresholds were established to detect the immunostaining as positive pixels and
background staining as negative pixels. Once conditions were established
for an immunohistochemical stain, the entire batch of slides was analyzed with the same parameters. The resulting color markup of the analysis was confirmed for each slide. All quantifications were done by a
blinded observer.
Slice electrophysiology. Methods for preparing acute brain slices for
assessment of CA1 synaptic function and plasticity were similar to our
previous methods (Norris and Scheff, 2009; Mathis et al., 2011). Briefly,
12-month-old WT and APP/PS1 KI mice were decapitated under CO2
anesthesia, and brains were rapidly removed and stored in ice-cold artificial cerebrospinal fluid (ACSF) containing: 124 mM NaCl, 2 mM KCl,
1.25 mM KH2PO4, 2 mM MgSO4, 26 mM NaHCO3, 10 mM dextrose,
saturated with 95% O2 and 5% CO2. Cerebral hemispheres were blocked,
mounted, and sectioned (400 m) in ice-cold Ca 2⫹-free ACSF with a
vibrating microtome (Leica Biosystems). Slices were then stored on nets
in a humidified interface holding chamber and bathed in CaCl2 (2 mM)containing ACSF (32°C) with saline vehicle or 30 M MW-151. After a
1.5–2 h incubation period, slices were transferred to a modified RC-22
chamber (Warner Instruments) affixed to the stage of a Nikon E600
microscope (Nikon Instruments) and perfused (1–2 ml/min) with oxygenated CaCl2 (2 mM)-containing ACSF (32°C). Synaptic responses were
evoked by electrical stimulation of CA3 Schaffer collaterals and recorded
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Figure 1. Increase in IL-1␤ levels in the APP/PS1 KI mouse as a function of animal age, and
selective attenuation of IL-1␤ by extended administration of MW-151 in a chronic intervention
paradigm. A, Neocortical tissue from WT (open circles) or APP/PS1 mice (closed circles) was
dissected from the brains of mice at different ages, and levels of IL-1␤ mRNA and protein were
determined by qPCR or MSD ELISA, respectively. B, APP/PS1 mice were treated in a chronic
intervention paradigm with either saline vehicle (veh; open bars) or MW-151 (closed bars; 2.5
mg/kg i.p. three times weekly) beginning at early age (6 months old). At the end of the treatment period, when mice were 11 months old, neocortical tissue was analyzed by MSD ELISA for
the levels of IL-1␤ and IL-10. MW-151 selectively attenuated the proinflammatory cytokine
IL-1␤, but not the anti-inflammatory cytokine IL-10. *p ⬍ 0.05 compared to WT mice at 11
months old.
in CA1 stratum radiatum as described previously (Norris and Scheff,
2009; Mathis et al. 2011). To generate synaptic strength curves, EPSP
amplitudes were measured at nine stimulus intensity levels (30, 50, 100,
150, 200, 250, 300, 400, and 500 mA) and plotted against corresponding
fiber volley (FV) amplitudes. For some slices, stimulus intensity was reset
after the synaptic strength curve to evoke a 1 mV EPSP every 30 s for at
least 20 min before the delivery of two 1 s duration trains of 100 Hz
stimulation (10 s intertrain interval) for induction of long term potentiation (LTP). Synaptic responses were then collected for an additional 60
min. All electrophysiological recordings were conducted and analyzed by
personnel who were blind to genotype and drug treatment conditions.
Statistics. Statistical analysis was conducted using GraphPad prism
software version 5 (GraphPad Software). Values are expressed as mean ⫾
SEM. Groups of two were compared by unpaired t test. Groups of three
or more were compared by one-way ANOVA, followed by the Bonferroni Multiple Comparison Test. Significance was defined as p ⬍ 0.05.
Synaptic strength curves were fit with a three parameter (i.e., max EPSP
amplitude, half-maximal FV amplitude, and curve slope) sigmoidal
function and compared across treatment groups using Z tests (Z values ⱖ
兩2兩 were considered statistically significant). For each slice, LTP amplitudes were averaged 50 – 60 min after delivery of 100 Hz stimulation and
normalized to the pre-100 Hz baseline. Significant effects of drug treatment on LTP were determined within genotype using paired t tests.
Differences in LTP amplitude between WT and APP/PS1 KI mice were
compared using an unpaired t test.
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Results
Validation of mechanism of action
endpoint in APPxPS1 mice
We reported previously (Hu et al., 2007)
that MW-151 is efficacious in a mouse
model of AD pathology that involves infusion of human oligomeric A␤1– 42 and represents disease in its early stages (Craft et al.,
2004a,b). However, the effect of the compound in an AD model that exhibits more
severe amyloid plaque pathology and agedependent disease progression had not been
examined. The first necessary step was to
choose an AD mouse model that exhibits
appropriate changes in the process that is
being targeted by our small molecule compound. Since the mechanism of action of
MW-151 is to attenuate cytokine overproduction from activated glia, it was important to
select an animal model that exhibits increases in glial activation and cytokine
production during the pathology progression. We selected the APP NLh/NLh ⫻
PS1 P264L/P264L mutant mouse model (APP/
PS1) originally developed at Cephalon
(Flood et al., 2002), where gene expression in
this humanized APP/PS1 double knock-in
model is driven by endogenous promoters of Figure 2. Chronic MW-151 administration attenuates microglial activation. A, Representative images of IBA1-stained microthe APP and PS-1 genes. This model preserves glia in cortex of 11-month old APP/PS1 mouse, demonstrating the positive pixel and nuclear algorithms used for quantification of
physiologically relevant APP expression levels the staining. A computer-generated markup of the algorithm is created by the ScanScope software, which validates the specificity
and demonstrates progressive AD pathology of the method. In the positive pixel algorithm, the microglia shown in shades of gray (indicating intensity of positive staining) is
without APP overproduction. Most impor- segregated from the background shown as black. The markup in the nuclear algorithm shows the reliable detection and quantifitantly, we verified that this model shows an cation of individual cells (shown by the black markup). B, C, The APP/PS1 mice treated with vehicle (veh; gray bars) show increased
microglial staining compared to WT mice treated with vehicle (white bars). MW-151 treatment of the APP/PS1 mice (black bars)
age-dependent increase in levels of proinreduced the microglial activation as assessed by either the stained area (B) or the number of stained microglia (C). *p ⬍ 0.05
flammatory cytokines above that of WT compared to vehicle-treated APP/PS1 mice. **p ⬍ 0.01 compared to vehicle-treated APP/PS1 mice.
mice. As shown in Figure 1A, the levels of
IL-1␤ mRNA and protein in the cortex inmicroglia and anti-GFAP antibody to label astrocytes. Immunocrease with age in both the WT and APP/PS1 KI mice, with the KI
stained sections were scanned and converted into a high-resolution
mice showing a significantly higher level of IL-1␤ at 11 months comdigital image using the Aperio ScanScope digital slide scanner and
pared to the WT mice. Thus, this is a relevant animal model in which
the positive pixels algorithm or the nuclear algorithm to quantify the
to test in vivo the efficacy of a cytokine response modulator.
immunohistochemical staining. The Aperio ScanScope enables
Extended administration of MW-151 in chronic intervention
paradigm reduces proinflammatory cytokine levels
Based on the time course of the cytokine rise, we designed a
chronic dosing, prevention study paradigm where MW-151 (2.5
mg/kg i.p.) or saline vehicle was administered three times per
week (Monday, Wednesday, Friday) beginning at 6 months
(when cytokine levels are just beginning to increase) and ending
at 11 months (when cytokine overproduction is easily apparent).
The mice tolerated well the extended administration of MW-151,
exhibiting no significant differences in survival or weight. As
shown in Figure 1 B, APP/PS1 KI mice administered MW-151
showed lower levels of brain IL-1␤ compared to vehicle-treated
mice, but no decrease in the anti-inflammatory cytokine IL-10.
These data confirm that MW-151 exhibits its mechanism of action, i.e., selective attenuation of brain proinflammatory cytokine
levels, in this animal model.
Chronic MW-151 administration attenuates microglial and
astrocyte activation
The effect of MW-151 treatment on glial activation was examined by
immunohistochemistry (IHC) using anti-IBA1 antibody to label

high-resolution image recognition and rigorous digital pathological
quantitation. Figure 2A shows a representative field of IBA1-stained
microglia in the cortex and digital images of the algorithms used to
calculate microglial activation characteristics. MW-151 treatment of
APP/PS1 KI mice reduced the microglial activation when data were
expressed as either the number of positive pixels (Fig. 2B) or the
number of stained cells/mm 2 (Fig. 2C).
In addition to effects on microglia activation, MW-151 administration also attenuated astrocyte activation. Figure 3A illustrates the
GFAP-labeled hemi-brain sections. MW-151 treatment reduced the
astrocyte activation in cortex (Fig. 3B) and hippocampus (data not
shown), as quantified from the IHC. Interestingly, MW-151 had no
effect on GFAP mRNA levels (Fig. 3C). MW-151 treatment did,
however, reduce the mRNA levels of two other astrocyte markers.
There was a significant decrease in S100B mRNA and a trend toward
a decrease in vimentin mRNA (Fig. 3C).
Chronic MW-151 administration prevents synaptic
protein loss
The ability of chronic administration of MW-151 to lead to beneficial neuronal changes was tested by measuring the levels of a
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Figure 3. Chronic MW-151 administration attenuates astrocyte activation. A, Representative images of GFAP-stained sections. B, The APP/PS1 mice treated with vehicle (veh; gray bars) show
increased astrocyte staining in cortex compared to WT mice treated with vehicle (white bars). MW-151 treatment of the APP/PS1 mice (black bars) reduced the astrocyte activation. C, MW-151
treatment had no effect on GFAP mRNA levels but did reduce mRNA levels of two other astrocyte markers, S100B and vimentin. **p ⬍ 0.01 compared to vehicle-treated APP/PS1 mice.
Table 1. Selective effects of MW-151 on inflammation-related gene
expression markers
⌬ ⬎ 20% p ⬍ 0.05 (*) Vehicle
IBA1
CD45
CD68
TLR2
TLR4
NOS2
TNF␣
TGF␤
IGF1
CD200
Fractalkine
HMGB1

2

*

2

*

1
2
2
2
1
1
2

*
*
*
*

100 ⫾ 9
100 ⫾ 8
100 ⫾ 9
100 ⫾ 13
100 ⫾ 15
100 ⫾ 15
100 ⫾ 12
100 ⫾ 7
100 ⫾ 28
100 ⫾ 9
100 ⫾ 9
100 ⫾ 9

MW-151

Gene/TaqMan assay ID

75 ⫾ 4
88 ⫾ 10
74 ⫾ 2
118 ⫾ 17
150 ⫾ 34
113 ⫾ 18
62 ⫾ 18
75 ⫾ 3
76 ⫾ 17
218 ⫾ 57
134 ⫾ 6
70 ⫾ 3

Aif1/Mm00479862_g1
Ptprc/Mm01293575_m1
Cd68/Mm00839636_g1
Tlr2/Mm00442346_m1
Tlr4/Mm00445273_m1
Nos2/Mm00440502_m1
Tnf/Mm00443258_m1
Tgfb1/Mm00441726_m1
Igf1/Mm00439561_m1
Cd200/Mm00487740_m1
Cx3cl1/Mm00436454_m1
Hmgb1/Mm00849805_gH

panel of synaptic protein markers by Western blot analysis. The
APP/PS1 KI model exhibits synaptic dysfunction as seen by a
reduction in the levels of synaptic proteins compared to WT mice
(Fig. 4). MW-151 treatment of APP/PS1 KI mice prevented the
loss of the synaptic proteins PSD95 (Fig. 4 A), synaptophysin
(Fig. 4 B), syntaxin (Fig. 4C), and SNAP25 (Fig. 4 D).

Figure 4. Chronic MW-151 administration prevents synaptic loss. Neocortex tissue was analyzed for the levels of synaptic proteins by Western blots. Compared to WT mice treated with
vehicle (veh; white bars), the APP/PS1 mice treated with vehicle (gray bars) show reduced levels
of the synaptic proteins PSD95 (A), synaptophysin (B), syntaxin (C), and SNAP25 (D). MW-151
treatment of the APP/PS1 mice protected against this loss of synaptic protein levels, restoring
the levels back toward WT values. *p ⬍ 0.05 compared to vehicle-treated APP/PS1 mice.

Selectivity of MW-151
In the AD brain, microglia exhibit a complex and heterogeneous
set of responses in attempts to restore homeostasis. Although our
understanding of the consequences of particular microglia responses to the neurodegenerative process in AD is limited, the
classical inflammatory activation state (termed M1) can lead to
overproduction of proinflammatory cytokines and subsequent
neuronal damage, while an alternative activation state (termed
M2) may be involved in attempts to prevent further damage or
promote tissue repair. To test the selectivity of MW-151 action in
terms of its effects on selected microglia and neuron responses,
we measured a panel of markers by quantitative PCR (qPCR) in
the cortex from the vehicle-treated or MW-151-treated APP/PS1
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Figure 5. Effects of short-term MW-151 treatment in acute intervention paradigm. Eleven-month-old mice were treated with either saline vehicle (veh; white bars, WT; gray bars, APP/PS1) or
with 2.5 mg/kg/d MW-151 i.p. (black bars, APP/PS) once daily for 1 week. Neocortex tissue was harvested and endpoints were measured. A, Short-term MW-151 treatment reduced the levels of
IL-1␤, but not IL-10, and had no effect on microglial (IBA1) or astrocyte (GFAP) activation. B, MW-151 treatment prevented the loss of PSD95 and synaptophysin, but the protection against syntaxin
and SNAP25 loss did not reach significance. *p ⬍ 0.05 compared to vehicle-treated APP/PS1 mice.

KI mice. The endpoints tested represent microglia markers, tolllike receptors, M1 and M2 endpoints, neuroimmune regulatory
molecules, and a damage-associated molecular pattern (DAMP)
molecule. Table 1 shows that MW-151 modulates some endpoints but not others. For example, TNF␣ is reduced but NOS2 is
not, even though both are considered M1 inflammatory molecules. Similarly, one of the M2 markers is changed (TGF␤), but
not the other (IGF1). Other M2 markers in the qPCR array (fizz,
Arg1, BDNF) could not be measured accurately because they
were at very low to undetected levels in the assay. These results
with M2 markers are consistent with our previous observations
(data not shown) that in the absence of external stressor stimuli,
this APP/PS1 KI mouse model does not express many of the
standard M2 markers to an appreciable degree. Other microglia
markers also showed selective responses in that IBA1 and CD68
are reduced but CD45 is not. The neuroimmune regulatory molecules CD200 and fractalkine are increased, and the DAMP
HMGB1 is decreased by MW-151 treatment. Although the functional significance of changes in these specific responses was not
explored as part of this study, these data confirm that MW-151 is
selective in its action and not a pan-suppressor of microglia and
neuron responses.
Short-term MW-151 treatment in acute
intervention paradigm
To test whether MW-151 is efficacious in older mice where disease pathology is already present, we administered MW-151 (2.5
mg/kg i.p.) or saline vehicle to 11-month-old mice once daily for
1 week. As shown in Figure 5A, short-term administration of
MW-151 in the acute intervention treatment paradigm attenuated IL-1␤ production without significant reductions in IL-10,
and had no effect on microglial (IBA1) or astrocyte (GFAP) acti-

vation. Analysis of synaptic protein levels (Fig. 5B) showed that
MW-151 significantly protected the brain against loss of PSD95
and synaptophysin but was less effective against loss of syntaxin
and SNAP25.
No effects of MW-151 on amyloid plaque load or A␤40
or A␤42
We examined the effect of MW-151 treatment on amyloid
plaque burden in both the chronic and acute dosing paradigms by staining brain sections with a polyclonal anti-A␤
N-terminal antibody. This antibody reacts with both A␤40
and A␤42 and is specific for human A␤. As shown in Figure
6 A, the 11-month-old APP/PS1 mice exhibit abundant numbers of amyloid plaques at this age, similar to previous reports
using this model (Flood et al., 2002; Anantharaman et al.,
2006; Murphy et al., 2007). Analysis of amyloid plaque staining in the cortex demonstrates that MW-151 treatment in
either the chronic intervention paradigm (Fig. 6 B) or the
acute intervention paradigm (Fig. 6C) had no significant effect
on amyloid plaque burden. There was also no effect of MW151 treatment on amyloid plaque load in the hippocampus
(data not shown). The lack of effect was seen when the data
were expressed either as percentage of the area stained with
anti-A␤ antibody or as number of plaques per mm 2. In addition, MW-151 treatment had no effect on the size of the amyloid plaques detected. To determine whether there was any
effect of MW-151 treatment on the levels of A␤, we prepared
PBS soluble, detergent soluble, and FA soluble fractions of
cortex and measured the levels of A␤40 and A␤42 by quantitative A␤ ELISA. No appreciable A␤ was detected in the detergent soluble fraction (data not shown). The amount of A␤40
or A␤42 in either the PBS soluble or FA soluble fractions was
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MW-151 treatment rescues
impairments in LTP
LTP is a widely studied experimental model
of synaptic plasticity implicated in learning
and memory (Bliss and Collingridge, 1993;
Malenka and Nicoll, 1999). Because of the
well established link between elevated proinflammatory cytokine levels and impairments in LTP, along with observations that
anti-cytokine strategies rescue LTP deficits
(Rowan et al., 2007; Lynch, 2010; Yirmiya
and Goshen, 2011), we investigated the effect of MW-151 on synaptic function and
plasticity by LTP measurements. Coronal
brain slices from 12-month-old APP/PS1 KI
mice were prepared and incubated for ⱖ1.5
h in oxygenated ACSF-containing saline vehicle or 30 M MW-151. Electrically evoked
EPSPs were obtained in hippocampal CA1
stratum radiatum, and LTP was induced
(Fig. 7A) using 100 Hz stimulus trains as
described previously (Mathis et al., 2011;
Norris and Scheff, 2009). Similar to previous findings with other APP/PS1 mouse
models (e.g., Trinchese et al., 2004), slices
from vehicle-treated APP/PS1 mice exhibited significantly reduced LTP compared to
slices from age-matched WT controls (n ⫽
5) (Fig. 7B,C). In contrast, LTP in MW151-treated slices from the APP/PS1 group
was similar in magnitude to the WT group
and significantly greater than that shown by
vehicle-treated APP/PS1 mice (p ⬍ 0.05).
No genotype or drug treatment effects were
observed for other synaptic function markers, including basal synaptic strength (Fig.
7D) and paired-pulse facilitation (data not
shown). The results suggest that MW-151
treatment selectively enhances synaptic
plasticity mechanisms in APP/PS1 KI mice.

Discussion
We report here several findings with important implications for future glia-targeted
AD therapeutic strategies. First, we show in
an APP/PS1 KI mouse model of AD pathology that pharmacological intervention with
a selective, small molecule inhibitor of glial
proinflammatory cytokine overproduction
is efficacious at attenuating microglial and
Figure 6. No effect of MW-151 treatment on A␤ pathology. A, Representative images of A␤-stained hemi-brain sections. B, C,
astrocyte activation and proinflammatory
In either the chronic intervention paradigm (B) or the acute intervention paradigm (C), MW-151 treatment of APP/PS1 mice did not
reduce the amyloid plaque load when measured as a percentage of the area stained or as the number of plaques per unit area. There cytokine levels, which prevents loss of synwere also no differences in the number of small (20 –300), medium (301–1000), or large (1001-⬁) amyloid plaques detected. aptic proteins and impairments in synaptic
MW-151 treatment of APP/PS1 mice also had no significant effect on the levels of soluble or aggregated forms of A␤, as measured plasticity (LTP). Second, there were no adverse effects observed with extended treatby levels of A␤40 or A␤42 in PBS-soluble and FA-soluble fractions. veh, Vehicle.
ment of aging mice with a therapy that
targets excessive proinflammatory cytokine
production. Third, the beneficial effects of
not significantly different in the APP/PS1 KI mice treated with
MW-151 occurred in the absence of a detectable change in amyloid
vehicle or MW-151 in either the chronic (Fig. 6 B) or acute
plaque load or in levels of soluble or aggregated forms of A␤40 or
(Fig. 6C) intervention paradigm. These data are consistent
A␤42 measured in PBS soluble and FA soluble neocortical fractions.
with the lack of effect on amyloid plaque burden and show that
Fourth, although MW-151 is effective when administration is
A␤ pathology overall was not significantly changed by MW151 treatment.
started at either early or later stages of disease pathology progression,
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Figure 7. MW-151 increases LTP in the hippocampus of 12-month-old APP/PS1 mice. A,
Representative CA3-CA1 synaptic responses from vehicle (veh)-treated and 30 M MW-151treated hippocampal slices from APP/PS1 mice, collected immediately before (dashed line) and
60 min after (solid line) LTP induction. B, Time plot of EPSP slope measures taken before and
after 100 Hz stimulation in slices from WT mice (white circles) and APP/PS1 mice treated with
(black circles) or without (gray circles) MW-151. C, Bar graph shows LTP levels across treatment
conditions. Number symbol (#) indicates a significant decrease ( p ⬍ 0.05) in LTP in vehicletreated slices from APP/PS1 mice compared to vehicle-treated slices from WT mice. Asterisk
indicates a significant increase ( p ⬍ 0.05) in LTP in MW-151-treated slices from APP/PS1 mice
relative to the APP/PS1 vehicle group. D, EPSP slope measures plotted against FV measures in
each treatment condition. No effects of genotype or MW-151 treatment on synaptic strength
were observed.

the compound is more effective in a preventative mode where administration is initiated before full later stage pathology is emerging.
Overall, our results show that selective inhibition of the increasing
glia proinflammatory cytokine response in early time windows of
disease progression is beneficial at maintaining synaptic function,
suggesting the importance of therapeutic time window considerations in future design of efficacy studies of neuroinflammationtargeted drugs.
The observation that MW-151 was more efficacious when administered in a preventative paradigm before onset of overt pathology implies that drugs that target neuroinflammation may be
most beneficial when used early in the course of disease pathogenesis. This is consistent with many studies demonstrating that
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glial activation and neuroinflammation are early events in AD
pathogenesis (e.g., see Cagnin et al., 2001; Mrak and Griffin,
2005; Griffin and Barger, 2010; Carter et al., 2012), recent
genome-wide association study data showing that many of the
genes associated with increased AD risk are inflammation-related
(Sleegers et al., 2010; Guerreiro et al., 2012), and epidemiological
and population-based clinical studies that suggest an association
between early use of nonsteroidal anti-inflammatory drugs
(NSAIDs) and reduced risk of developing AD (McGeer et al.,
1996; in’t Veld et al., 2001; Zandi and Breitner, 2001).
In addition, analysis of data (Breitner et al., 2011; Leoutsakos
et al., 2012) from the randomized clinical trial ADAPT (Alzheimer’s Disease Anti-inflammatory Prevention Trial) suggest that
the treatment effects of NSAIDs differ depending on the stage of
disease, with potential beneficial effects in asymptomatic individuals with little or no cognitive decline at the time of drug use, but
harmful effects in later stages of AD pathogenesis. Although
MW-151 is not an NSAID, the results reported here are consistent with the idea that suppression of CNS inflammation is likely
to be effective as a prevention strategy before the self-propagating, proinflammatory cytokine cycle is too far advanced
during disease progression. However, MW-151 was also able to
block cytokine production and prevent the decrease in some synaptic proteins even when administered at a later stage of pathology progression (to 11-month old mice for only a week). These
initial observations will need to be followed up with more detailed studies on the therapeutic window, but they suggest that
future anti-inflammatory strategies aimed at selective fine tuning
of neuroinflammation might be useful not only to prevent or
delay onset of AD, but potentially as part of therapeutic strategies
to treat existing disease, which would involve co-therapy with
other drugs.
MW-151 was discovered using a functional in vivo screen
(Ralay Ranaivo et al., 2006; Wing et al., 2006; Hu et al., 2007; Van
Eldik et al., 2007) that employed an animal model of injury induced by toxic aggregates of human A␤1– 42. That model lacked
an age-dependent progressive pathology and did not have an
amyloid plaque-rich environment. The APP/PS1 KI model used
here exhibits progressive amyloid plaque deposition, beginning
at around 9 months of age and increasing with age (Flood et al.,
2002; Anantharaman et al., 2006; Murphy et al., 2007). This
model also exhibits progressive pathological alterations in bidirectional synaptic plasticity, cognitive measures, synaptosomal
membrane lipids, and oxidative stress markers as a function of
animal development and maturation (Anantharaman et al.,
2006; Chang et al., 2006; Bruce-Keller et al., 2011). We have
shown here that the APP/PS1 KI model also demonstrates an
early and progressive increase in brain proinflammatory cytokine
levels, and that dampening of the proinflammatory cytokine production and the associated glial activation is beneficial to synaptic
function. In this regard, it is interesting to note that these beneficial effects of MW-151 occurred in the absence of a detectable
effect on amyloid plaque load or a change in PBS soluble or FA
soluble A␤40/42 levels, demonstrating that MW-151 treatment
does not shift the levels of soluble toxic A␤ oligomers or insoluble
fibrils.
There is inconsistency in the literature with respect to the
effect of blocking cytokine signaling on A␤ pathology. Some
studies have reported that interference with cytokine signaling by
anti-inflammatory drug treatment or genetic deletion strategies
results in reduced amyloid plaque load (Lim et al., 2000; Jantzen
et al., 2002; Yan et al., 2003; Morihara et al., 2005; He et al., 2007;
Yamamoto et al., 2007). However, other studies have shown that
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cytokine-suppressing strategies can reduce brain inflammatory
responses and attenuate markers of neuronal pathology with little or no effect on amyloid plaque pathology (Ralay Ranaivo et al.,
2006; Kitazawa et al., 2011). Therefore, it is possible that an impact on amyloid plaques might be due to the model being used,
the pharmacodynamic profile of the particular drug, the therapeutic time window of treatment and pathology development, or
any combination of these variables. Our results with MW-151
pharmacodynamics in this particular model clearly demonstrate
that synaptic and glia endpoints, related respectively to efficacy
and in vivo mechanism of drug action, can be modulated independently of effects on A␤. The linkage to tau pathology or its
interface with A␤ pathology (Zilka et al., 2012) cannot be addressed in this model because the APP/PS1 KI mouse lacks
AD-relevant tau pathology. Thus, the interplay between glia proinflammatory cytokine-linked neuropathologies and ADrelevant tau neurofibrillary pathology remains to be addressed in
future studies.
The linkage between changes in proinflammatory cytokine levels
and neurologic outcomes, revealed by the improvement in synaptic
endpoints (synaptic protein levels and LTP) after attenuation of proinflammatory cytokine levels by MW-151 treatment, is consistent
with previous reports of MW-151 efficacy in other rodent CNS injury models, including oligomeric A␤-induced injury (Hu et al.,
2007), kainic acid-induced seizures (Somera-Molina et al., 2007, 2009),
Traumatic Brain Injury models (Lloyd et al., 2008; Chrzaszcz et al.,
2010), and the Experimental Autoimmune Encephalomyelitis model of
multiple sclerosis (Karpus et al., 2008). These previous studies documented that MW-151 efficacy at reducing injury-induced upregulation
of proinflammatory cytokine levels was associated with a reduction in
long-term neuronal injury and attenuation of hippocampal-dependent
cognitive deficits. Our findings are also consistent with reports that have
linked other anti-neuroinflammatory interventions with changes in
synaptic plasticity. For example, pharmacological interventions and/or
genetic manipulations that suppress proinflammatory cytokine signaling normalize synaptic function in primary neural
cultures (Sama et al., 2008) and ameliorate LTP deficits associated with aging (Griffin et al., 2006; Cowley et al., 2012) and
A␤ (Rowan et al., 2007; Kotilinek et al., 2008; Yirmiya et al.,
2011).
Overall, the data reported here add to the growing body of
evidence that has identified dysregulated glial activation and
proinflammatory cytokine overproduction as a common early
pathophysiologic mechanism and potential therapeutic target in
diverse neurodegenerative disorders. In addition, the results extend this state of knowledge to therapeutic intervention possibilities, especially the importance of therapeutic time window
considerations in the design of intervention strategies.
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